



ASX Announcement

19 August 2015

iQ3Corp. announces investment banking arm

iQ3Corp Ltd (ASX:IQ3) today announced that through its fully owned subsidiary in the U.S., iQ Capital LLC, it is applying to obtain the necessary licenses to operate an investment banking business dedicated to life sciences.

For this reason it has mandated its advisors to commence regulatory filings with a scope to offer the following financial services:

Debt or equity offerings through public or private placement.

- > Pricing of securities in the debt and equity offerings
- > Origination, which deals with equity capital markets and debt capital markets
- > Underwriting
- > Marketing
- > Structuring
- > Syndication
- > Managing the allocation and stabilisation activities of offerings

Mergers, acquisitions and financial restructuring.

- > Tender offers
- > Selling assets
- > Corporate reorganisation or divestitures
- > Transactions involving business combinations, which include rendering opinions solvency and fairness opinions

General Broker and Dealer Services.

The investment bank – iQ Capital – aims to realise cross border arbitrage between Australian biotech assets and American biotechnology institutional investors.

CEO of iQ3Corp., Dr. George Syrmalis – who previously founded and led one of Europe’s first and foremost Biotechnology companies, The Bionuclear Group SA – says, ‘this represents a major milestone for our investors, the biotech industry, our team and the people we work with.’

‘I believe this is an extremely strategic and innovative position to take within the industry, and demonstrates our whole-hearted commitment towards developing



the medicines of the future.'

iQ3Corp. expects iQ Capital to gradually commence operational activity in approximately 90 days and fulfill its regulatory commitments within six to nine months.

For further information:

Investors

iQ3Corp Investor Relations Team
Email: investor.relations@iq3corp.com
Phone: +61 2 8239 5400

Media

Angela Maher
Director, Marketing, Media & Communications
Email: angela.maher@theiqgroup.com.au
Mobile: +61 438 519 916

About iQ3Corp Limited:

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.

Disclaimer

Subject to any continuing obligations under the laws of the Commonwealth of Australia or the ASX listing rules, iQ3Corp Ltd (iQ3Corp or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements. The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQ3Corp and detailed in this announcement represents the Company's strategic planning and decision-making practices and are based on current expectations. iQ3Corp's business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQ3Corp to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQ3Corp's business, its associated risks and operations can be found in its periodic announcements to ASX.